APO Research
Talk to an analyst

APO RESEARCH · REPORT

Primary Biliary Cirrhosis Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Primary Biliary Cirrhosis Drug Industry Growth and Trends Forecast to 2032

19 December 2025108 pages

Choose your research edition.

Industry ResearchPrimary Biliary Cirrhosis Drug Industry Research Report 2026126 pages · $2,950 USDIndustry Growth & TrendsGlobal Primary Biliary Cirrhosis Drug Industry Growth and Trends Forecast to 2032108 pages · $3,450 USDMarket StructureGlobal Primary Biliary Cirrhosis Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Primary Biliary Cirrhosis Drug Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Primary Biliary Cirrhosis Drug Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Primary Biliary Cirrhosis Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Primary Biliary Cirrhosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Primary Biliary Cirrhosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Primary Biliary Cirrhosis Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Primary Biliary Cirrhosis Drug include AlbireoPharma, CymaBay Therapeutics, Inc., Dr. Falk Pharma GmbH, Enanta Pharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., MediGene AG, NGM Biopharmaceuticals, Inc., Virobay Inc. and GlaxoSmithKline Plc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Primary Biliary Cirrhosis Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Primary Biliary Cirrhosis Drug market size, estimates, and forecasts are presented in terms of sales volume (W Units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Primary Biliary Cirrhosis Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Primary Biliary Cirrhosis Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Primary Biliary Cirrhosis Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Primary Biliary Cirrhosis Drug Market by Company

AlbireoPharma

CymaBay Therapeutics, Inc.

Dr. Falk Pharma GmbH

Enanta Pharmaceuticals, Inc.

Intercept Pharmaceuticals, Inc.

MediGene AG

NGM Biopharmaceuticals, Inc.

Virobay Inc.

GlaxoSmithKline Plc

Johnson & Johnson

Primary Biliary Cirrhosis Drug Segment by Type

Budesonide

NGM-282

MBX-8025

GSK-2330672

FFP-104

Others

Primary Biliary Cirrhosis Drug Segment by Application

Clinic

Hospital

Others

Primary Biliary Cirrhosis Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Primary Biliary Cirrhosis Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Primary Biliary Cirrhosis Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Primary Biliary Cirrhosis Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Primary Biliary Cirrhosis Drug manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Primary Biliary Cirrhosis Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Budesonide Table 2. Major Company of NGM-282 Table 3. Major Company of MBX-8025 Table 4. Major Company of GSK-2330672 Table 5. Major Company of FFP-104 Table 6. Major Company of Others Table 7. Global Primary Biliary Cirrhosis Drug Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 8. Global Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (W Units) Table 9. Global Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Type (2021-2026) Table 10. Global Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (US$ Million) Table 11. Global Primary Biliary Cirrhosis Drug Sales Market Share in Value by Type (2021-2026) Table 12. Global Primary Biliary Cirrhosis Drug Price by Type (2021-2026) & (US$/Unit) Table 13. Global Primary Biliary Cirrhosis Drug Sales by Type (2027-2032) & (W Units) Table 14. Global Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Type (2027-2032) Table 15. Global Primary Biliary Cirrhosis Drug Sales by Type (2027-2032) & (US$ Million) Table 16. Global Primary Biliary Cirrhosis Drug Sales Market Share in Value by Type (2027-2032) Table 17. Global Primary Biliary Cirrhosis Drug Price by Type (2027-2032) & (US$/Unit) Table 18. North America Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (W Units) Table 19. North America Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (US$ Million) Table 20. Europe Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (W Units) Table 21. Europe Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (US$ Million) Table 22. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (W Units) Table 23. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (US$ Million) Table 24. Latin America Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (W Units) Table 25. Latin America Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (US$ Million) Table 26. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (W Units) Table 27. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Type (2021-2026) & (US$ Million) Table 28. Primary Biliary Cirrhosis Drug Industry Trends Table 29. Primary Biliary Cirrhosis Drug Industry Drivers Table 30. Primary Biliary Cirrhosis Drug Industry Opportunities and Challenges Table 31. Primary Biliary Cirrhosis Drug Industry Restraints Table 32. Global Primary Biliary Cirrhosis Drug Sales Revenue by Company (US$ Million) & (2021-2026) Table 33. Global Primary Biliary Cirrhosis Drug Revenue Market Share by Company (2021-2026) Table 34. Global Primary Biliary Cirrhosis Drug Sales by Company (2021-2026) & (W Units) Table 35. Global Primary Biliary Cirrhosis Drug Sales Share by Company (2021-2026) Table 36. Global Primary Biliary Cirrhosis Drug Market Price by Company (2021-2026) & (US$/Unit) Table 37. Global Primary Biliary Cirrhosis Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 38. Global Primary Biliary Cirrhosis Drug Major Company Production Sites and Headquarters Table 39. Global Primary Biliary Cirrhosis Drug Company, Product Type & Application Table 40. Global Primary Biliary Cirrhosis Drug Company Establishment Date Table 41. Global Company Market Concentration Ratio (CR5 and HHI) Table 42. Global Primary Biliary Cirrhosis Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 43. Global Primary Biliary Cirrhosis Drug Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 44. Global Primary Biliary Cirrhosis Drug Sales by Region (2021-2026) & (W Units) Table 45. Global Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Region (2021-2026) Table 46. Global Primary Biliary Cirrhosis Drug Sales by Region (2021-2026) & (US$ Million) Table 47. Global Primary Biliary Cirrhosis Drug Sales Market Share in Value by Region (2021-2026) Table 48. Global Primary Biliary Cirrhosis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 49. Global Primary Biliary Cirrhosis Drug Sales by Region (2027-2032) & (W Units) Table 50. Global Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Region (2027-2032) Table 51. Global Primary Biliary Cirrhosis Drug Sales by Region (2027-2032) & (US$ Million) Table 52. Global Primary Biliary Cirrhosis Drug Sales Market Share in Value by Region (2027-2032) Table 53. Global Primary Biliary Cirrhosis Drug Sales (W Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2027-2032) Table 54. Global Primary Biliary Cirrhosis Drug Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 55. Global Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (W Units) Table 56. Global Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Application (2021-2026) Table 57. Global Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (US$ Million) Table 58. Global Primary Biliary Cirrhosis Drug Sales Market Share in Value by Application (2021-2026) Table 59. Global Primary Biliary Cirrhosis Drug Price by Application (2021-2026) & (US$/Unit) Table 60. Global Primary Biliary Cirrhosis Drug Sales by Application (2027-2032) & (W Units) Table 61. Global Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Application (2027-2032) Table 62. Global Primary Biliary Cirrhosis Drug Sales by Application (2027-2032) & (US$ Million) Table 63. Global Primary Biliary Cirrhosis Drug Sales Market Share in Value by Application (2027-2032) Table 64. Global Primary Biliary Cirrhosis Drug Price by Application (2027-2032) & (US$/Unit) Table 65. North America Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (W Units) Table 66. North America Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (US$ Million) Table 67. Europe Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (W Units) Table 68. Europe Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (US$ Million) Table 69. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (W Units) Table 70. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (US$ Million) Table 71. Latin America Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (W Units) Table 72. Latin America Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (US$ Million) Table 73. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (W Units) Table 74. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Application (2021-2026) & (US$ Million) Table 75. AlbireoPharma Company Information Table 76. AlbireoPharma Business Overview Table 77. AlbireoPharma Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 78. AlbireoPharma Primary Biliary Cirrhosis Drug Product Portfolio Table 79. AlbireoPharma Recent Development Table 80. CymaBay Therapeutics, Inc. Company Information Table 81. CymaBay Therapeutics, Inc. Business Overview Table 82. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 83. CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 84. CymaBay Therapeutics, Inc. Recent Development Table 85. Dr. Falk Pharma GmbH Company Information Table 86. Dr. Falk Pharma GmbH Business Overview Table 87. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Portfolio Table 89. Dr. Falk Pharma GmbH Recent Development Table 90. Enanta Pharmaceuticals, Inc. Company Information Table 91. Enanta Pharmaceuticals, Inc. Business Overview Table 92. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 94. Enanta Pharmaceuticals, Inc. Recent Development Table 95. Intercept Pharmaceuticals, Inc. Company Information Table 96. Intercept Pharmaceuticals, Inc. Business Overview Table 97. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 98. Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 99. Intercept Pharmaceuticals, Inc. Recent Development Table 100. MediGene AG Company Information Table 101. MediGene AG Business Overview Table 102. MediGene AG Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 103. MediGene AG Primary Biliary Cirrhosis Drug Product Portfolio Table 104. MediGene AG Recent Development Table 105. NGM Biopharmaceuticals, Inc. Company Information Table 106. NGM Biopharmaceuticals, Inc. Business Overview Table 107. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 108. NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 109. NGM Biopharmaceuticals, Inc. Recent Development Table 110. Virobay Inc. Company Information Table 111. Virobay Inc. Business Overview Table 112. Virobay Inc. Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 113. Virobay Inc. Primary Biliary Cirrhosis Drug Product Portfolio Table 114. Virobay Inc. Recent Development Table 115. GlaxoSmithKline Plc Company Information Table 116. GlaxoSmithKline Plc Business Overview Table 117. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 118. GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Portfolio Table 119. GlaxoSmithKline Plc Recent Development Table 120. Johnson & Johnson Company Information Table 121. Johnson & Johnson Business Overview Table 122. Johnson & Johnson Primary Biliary Cirrhosis Drug Sales (W Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 123. Johnson & Johnson Primary Biliary Cirrhosis Drug Product Portfolio Table 124. Johnson & Johnson Recent Development Table 125. North America Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 126. North America Primary Biliary Cirrhosis Drug Sales by Country (2021-2026) & (W Units) Table 127. North America Primary Biliary Cirrhosis Drug Sales Market Share by Country (2021-2026) Table 128. North America Primary Biliary Cirrhosis Drug Sales Forecast by Country (2027-2032) & (W Units) Table 129. North America Primary Biliary Cirrhosis Drug Sales Market Share Forecast by Country (2027-2032) Table 130. North America Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 131. North America Primary Biliary Cirrhosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 132. North America Primary Biliary Cirrhosis Drug Market Share by Country (2021-2026) Table 133. North America Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 134. North America Primary Biliary Cirrhosis Drug Market Share Forecast by Country (2027-2032) Table 135. Europe Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 136. Europe Primary Biliary Cirrhosis Drug Sales by Country (2021-2026) & (W Units) Table 137. Europe Primary Biliary Cirrhosis Drug Sales Market Share by Country (2021-2026) Table 138. Europe Primary Biliary Cirrhosis Drug Sales Forecast by Country (2027-2032) & (W Units) Table 139. Europe Primary Biliary Cirrhosis Drug Sales Market Share Forecast by Country (2027-2032) Table 140. Europe Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 141. Europe Primary Biliary Cirrhosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 142. Europe Primary Biliary Cirrhosis Drug Market Share by Country (2021-2026) Table 143. Europe Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 144. Europe Primary Biliary Cirrhosis Drug Market Share Forecast by Country (2027-2032) Table 145. Asia-Pacific Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 146. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Country (2021-2026) & (W Units) Table 147. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share by Country (2021-2026) Table 148. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Forecast by Country (2027-2032) & (W Units) Table 149. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share Forecast by Country (2027-2032) Table 150. Asia-Pacific Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 151. Asia-Pacific Primary Biliary Cirrhosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 152. Asia-Pacific Primary Biliary Cirrhosis Drug Market Share by Country (2021-2026) Table 153. Asia-Pacific Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 154. Asia-Pacific Primary Biliary Cirrhosis Drug Market Share Forecast by Country (2027-2032) Table 155. Latin America Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 156. Latin America Primary Biliary Cirrhosis Drug Sales by Country (2021-2026) & (W Units) Table 157. Latin America Primary Biliary Cirrhosis Drug Sales Market Share by Country (2021-2026) Table 158. Latin America Primary Biliary Cirrhosis Drug Sales Forecast by Country (2027-2032) & (W Units) Table 159. Latin America Primary Biliary Cirrhosis Drug Sales Market Share Forecast by Country (2027-2032) Table 160. Latin America Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 161. Latin America Primary Biliary Cirrhosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 162. Latin America Primary Biliary Cirrhosis Drug Market Share by Country (2021-2026) Table 163. Latin America Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 164. Latin America Primary Biliary Cirrhosis Drug Market Share Forecast by Country (2027-2032) Table 165. Middle East and Africa Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country (W Units): 2021 VS 2025 VS 2032 Table 166. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country (2021-2026) & (W Units) Table 167. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share by Country (2021-2026) Table 168. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Forecast by Country (2027-2032) & (W Units) Table 169. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share Forecast by Country (2027-2032) Table 170. Middle East and Africa Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 171. Middle East and Africa Primary Biliary Cirrhosis Drug Market Size by Country (2021-2026) & (US$ Million) Table 172. Middle East and Africa Primary Biliary Cirrhosis Drug Market Share by Country (2021-2026) Table 173. Middle East and Africa Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 174. Middle East and Africa Primary Biliary Cirrhosis Drug Market Share Forecast by Country (2027-2032) Table 175. Key Raw Materials Table 176. Raw Materials Key Suppliers Table 177. Primary Biliary Cirrhosis Drug Distributors List Table 178. Primary Biliary Cirrhosis Drug Customers List Table 179. Research Programs/Design for This Report Table 180. Authors List of This Report Table 181. Secondary Sources Table 182. Primary Sources List of Figures Figure 1. Primary Biliary Cirrhosis Drug Image Figure 2. Global Primary Biliary Cirrhosis Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Primary Biliary Cirrhosis Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Primary Biliary Cirrhosis Drug Sales (2021-2032) & (W Units) Figure 5. Budesonide Image Figure 6. Global Budesonide Sales YoY Growth (2021-2032) & (W Units) Figure 7. NGM-282 Image Figure 8. Global NGM-282 Sales YoY Growth (2021-2032) & (W Units) Figure 9. MBX-8025 Image Figure 10. Global MBX-8025 Sales YoY Growth (2021-2032) & (W Units) Figure 11. GSK-2330672 Image Figure 12. Global GSK-2330672 Sales YoY Growth (2021-2032) & (W Units) Figure 13. FFP-104 Image Figure 14. Global FFP-104 Sales YoY Growth (2021-2032) & (W Units) Figure 15. Others Image Figure 16. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 17. Global Primary Biliary Cirrhosis Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 18. Global Primary Biliary Cirrhosis Drug Market Share by Type 2025 VS 2032 Figure 19. North America Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Type in 2025 Figure 20. North America Primary Biliary Cirrhosis Drug Sales Market Share in Value by Type in 2025 Figure 21. Europe Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Type in 2025 Figure 22. Europe Primary Biliary Cirrhosis Drug Sales Market Share in Value by Type in 2025 Figure 23. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Type in 2025 Figure 24. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share in Value by Type in 2025 Figure 25. Latin America Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Type in 2025 Figure 26. Latin America Primary Biliary Cirrhosis Drug Sales Market Share in Value by Type in 2025 Figure 27. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Type in 2025 Figure 28. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share in Value by Type in 2025 Figure 29. Global Top 5 and 10 Primary Biliary Cirrhosis Drug Players Market Share by Revenue in 2025 Figure 30. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 31. Clinic Image Figure 32. Global Clinic Sales YoY Growth (2021-2032) & (W Units) Figure 33. Hospital Image Figure 34. Global Hospital Sales YoY Growth (2021-2032) & (W Units) Figure 35. Others Image Figure 36. Global Others Sales YoY Growth (2021-2032) & (W Units) Figure 37. Global Primary Biliary Cirrhosis Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 38. Global Primary Biliary Cirrhosis Drug Market Share by Application 2025 VS 2032 Figure 39. North America Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Application in 2025 Figure 40. North America Primary Biliary Cirrhosis Drug Sales Market Share in Value by Application in 2025 Figure 41. Europe Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Application in 2025 Figure 42. Europe Primary Biliary Cirrhosis Drug Sales Market Share in Value by Application in 2025 Figure 43. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Application in 2025 Figure 44. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Market Share in Value by Application in 2025 Figure 45. Latin America Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Application in 2025 Figure 46. Latin America Primary Biliary Cirrhosis Drug Sales Market Share in Value by Application in 2025 Figure 47. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share in Volume by Application in 2025 Figure 48. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Market Share in Value by Application in 2025 Figure 49. North America Primary Biliary Cirrhosis Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 50. North America Primary Biliary Cirrhosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. North America Primary Biliary Cirrhosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. North America Primary Biliary Cirrhosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Europe Primary Biliary Cirrhosis Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 54. Europe Primary Biliary Cirrhosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Europe Primary Biliary Cirrhosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Europe Primary Biliary Cirrhosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 58. Asia-Pacific Primary Biliary Cirrhosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Asia-Pacific Primary Biliary Cirrhosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Asia-Pacific Primary Biliary Cirrhosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. Latin America Primary Biliary Cirrhosis Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 62. Latin America Primary Biliary Cirrhosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 63. Latin America Primary Biliary Cirrhosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 64. Latin America Primary Biliary Cirrhosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 65. Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country: 2021 VS 2025 VS 2032 (W Units) Figure 66. Middle East and Africa Primary Biliary Cirrhosis Drug Sales Share by Country: 2021 VS 2025 VS 2032 Figure 67. Middle East and Africa Primary Biliary Cirrhosis Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 68. Middle East and Africa Primary Biliary Cirrhosis Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 69. Primary Biliary Cirrhosis Drug Value Chain Figure 70. Key Raw Materials Price Figure 71. Manufacturing Cost Structure Figure 72. Primary Biliary Cirrhosis Drug Production Mode & Process Figure 73. Direct Comparison with Distribution Share Figure 74. Distributors Profiles Figure 75. Years Considered Figure 76. Research Process Figure 77. Key Executives Interviewed

Scope & coverage.

Types
  • Budesonide
  • NGM-282
  • MBX-8025
  • GSK-2330672
  • FFP-104
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • AlbireoPharma
  • CymaBay Therapeutics, Inc.
  • Dr. Falk Pharma GmbH
  • Enanta Pharmaceuticals, Inc.
  • Intercept Pharmaceuticals, Inc.
  • MediGene AG
  • NGM Biopharmaceuticals, Inc.
  • Virobay Inc.
  • GlaxoSmithKline Plc
  • Johnson & Johnson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Primary Biliary Cirrhosis Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Primary Biliary Cirrhosis Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Primary Biliary Cirrhosis Drug Market by Type
  6. 1.3.1 Budesonide
  7. 1.3.2 NGM-282
  8. 1.3.3 MBX-8025
  9. 1.3.4 GSK-2330672
  10. 1.3.5 FFP-104
  11. 1.3.6 Others
  12. 1.4 Global Primary Biliary Cirrhosis Drug Market Size by Type
  13. 1.4.1 Global Primary Biliary Cirrhosis Drug Market Size Overview by Type (2021-2032)
  14. 1.4.2 Global Primary Biliary Cirrhosis Drug Historic Market Size Review by Type (2021-2026)
  15. 1.4.3 Global Primary Biliary Cirrhosis Drug Forecasted Market Size by Type (2027-2032)
  16. 1.5 Key Regions Market Size by Type
  17. 1.5.1 North America Primary Biliary Cirrhosis Drug Sales Breakdown by Type (2021-2026)
  18. 1.5.2 Europe Primary Biliary Cirrhosis Drug Sales Breakdown by Type (2021-2026)
  19. 1.5.3 Asia-Pacific Primary Biliary Cirrhosis Drug Sales Breakdown by Type (2021-2026)
  20. 1.5.4 South America Primary Biliary Cirrhosis Drug Sales Breakdown by Type (2021-2026)
  21. 1.5.5 Middle East and Africa Primary Biliary Cirrhosis Drug Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Primary Biliary Cirrhosis Drug Industry Trends
  2. 2.2 Primary Biliary Cirrhosis Drug Industry Drivers
  3. 2.3 Primary Biliary Cirrhosis Drug Industry Opportunities and Challenges
  4. 2.4 Primary Biliary Cirrhosis Drug Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Primary Biliary Cirrhosis Drug Revenue (2021-2026)
  2. 3.2 Global Top Players by Primary Biliary Cirrhosis Drug Sales (2021-2026)
  3. 3.3 Global Top Players by Primary Biliary Cirrhosis Drug Price (2021-2026)
  4. 3.4 Global Primary Biliary Cirrhosis Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Primary Biliary Cirrhosis Drug Major Company Production Sites & Headquarters
  6. 3.6 Global Primary Biliary Cirrhosis Drug Company, Product Type & Application
  7. 3.7 Global Primary Biliary Cirrhosis Drug Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Primary Biliary Cirrhosis Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Primary Biliary Cirrhosis Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Primary Biliary Cirrhosis Drug Tier 1, Tier 2, and Tier 3
4 Primary Biliary Cirrhosis Drug Regional Status and Outlook
  1. 4.1 Global Primary Biliary Cirrhosis Drug Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Primary Biliary Cirrhosis Drug Historic Market Size by Region
  3. 4.2.1 Global Primary Biliary Cirrhosis Drug Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Primary Biliary Cirrhosis Drug Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Primary Biliary Cirrhosis Drug Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Primary Biliary Cirrhosis Drug Forecasted Market Size by Region
  7. 4.3.1 Global Primary Biliary Cirrhosis Drug Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Primary Biliary Cirrhosis Drug Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Primary Biliary Cirrhosis Drug Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Primary Biliary Cirrhosis Drug by Application
  1. 5.1 Primary Biliary Cirrhosis Drug Market by Application
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Primary Biliary Cirrhosis Drug Market Size by Application
  6. 5.2.1 Global Primary Biliary Cirrhosis Drug Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Primary Biliary Cirrhosis Drug Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Primary Biliary Cirrhosis Drug Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Primary Biliary Cirrhosis Drug Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Primary Biliary Cirrhosis Drug Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Primary Biliary Cirrhosis Drug Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Primary Biliary Cirrhosis Drug Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Primary Biliary Cirrhosis Drug Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 AlbireoPharma
  2. 6.1.1 AlbireoPharma Company Information
  3. 6.1.2 AlbireoPharma Business Overview
  4. 6.1.3 AlbireoPharma Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 AlbireoPharma Primary Biliary Cirrhosis Drug Product Portfolio
  6. 6.1.5 AlbireoPharma Recent Developments
  7. 6.2 CymaBay Therapeutics, Inc.
  8. 6.2.1 CymaBay Therapeutics, Inc. Company Information
  9. 6.2.2 CymaBay Therapeutics, Inc. Business Overview
  10. 6.2.3 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 CymaBay Therapeutics, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  12. 6.2.5 CymaBay Therapeutics, Inc. Recent Developments
  13. 6.3 Dr. Falk Pharma GmbH
  14. 6.3.1 Dr. Falk Pharma GmbH Company Information
  15. 6.3.2 Dr. Falk Pharma GmbH Business Overview
  16. 6.3.3 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Dr. Falk Pharma GmbH Primary Biliary Cirrhosis Drug Product Portfolio
  18. 6.3.5 Dr. Falk Pharma GmbH Recent Developments
  19. 6.4 Enanta Pharmaceuticals, Inc.
  20. 6.4.1 Enanta Pharmaceuticals, Inc. Company Information
  21. 6.4.2 Enanta Pharmaceuticals, Inc. Business Overview
  22. 6.4.3 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Enanta Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  24. 6.4.5 Enanta Pharmaceuticals, Inc. Recent Developments
  25. 6.5 Intercept Pharmaceuticals, Inc.
  26. 6.5.1 Intercept Pharmaceuticals, Inc. Company Information
  27. 6.5.2 Intercept Pharmaceuticals, Inc. Business Overview
  28. 6.5.3 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Intercept Pharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  30. 6.5.5 Intercept Pharmaceuticals, Inc. Recent Developments
  31. 6.6 MediGene AG
  32. 6.6.1 MediGene AG Company Information
  33. 6.6.2 MediGene AG Business Overview
  34. 6.6.3 MediGene AG Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 MediGene AG Primary Biliary Cirrhosis Drug Product Portfolio
  36. 6.6.5 MediGene AG Recent Developments
  37. 6.7 NGM Biopharmaceuticals, Inc.
  38. 6.7.1 NGM Biopharmaceuticals, Inc. Company Information
  39. 6.7.2 NGM Biopharmaceuticals, Inc. Business Overview
  40. 6.7.3 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 NGM Biopharmaceuticals, Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  42. 6.7.5 NGM Biopharmaceuticals, Inc. Recent Developments
  43. 6.8 Virobay Inc.
  44. 6.8.1 Virobay Inc. Company Information
  45. 6.8.2 Virobay Inc. Business Overview
  46. 6.8.3 Virobay Inc. Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Virobay Inc. Primary Biliary Cirrhosis Drug Product Portfolio
  48. 6.8.5 Virobay Inc. Recent Developments
  49. 6.9 GlaxoSmithKline Plc
  50. 6.9.1 GlaxoSmithKline Plc Company Information
  51. 6.9.2 GlaxoSmithKline Plc Business Overview
  52. 6.9.3 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 GlaxoSmithKline Plc Primary Biliary Cirrhosis Drug Product Portfolio
  54. 6.9.5 GlaxoSmithKline Plc Recent Developments
  55. 6.10 Johnson & Johnson
  56. 6.10.1 Johnson & Johnson Company Information
  57. 6.10.2 Johnson & Johnson Business Overview
  58. 6.10.3 Johnson & Johnson Primary Biliary Cirrhosis Drug Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Johnson & Johnson Primary Biliary Cirrhosis Drug Product Portfolio
  60. 6.10.5 Johnson & Johnson Recent Developments
7 North America by Country
  1. 7.1 North America Primary Biliary Cirrhosis Drug Sales by Country
  2. 7.1.1 North America Primary Biliary Cirrhosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Primary Biliary Cirrhosis Drug Sales by Country (2021-2026)
  4. 7.1.3 North America Primary Biliary Cirrhosis Drug Sales Forecast by Country (2027-2032)
  5. 7.2 North America Primary Biliary Cirrhosis Drug Market Size by Country
  6. 7.2.1 North America Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Primary Biliary Cirrhosis Drug Market Size by Country (2021-2026)
  8. 7.2.3 North America Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Primary Biliary Cirrhosis Drug Sales by Country
  2. 8.1.1 Europe Primary Biliary Cirrhosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Primary Biliary Cirrhosis Drug Sales by Country (2021-2026)
  4. 8.1.3 Europe Primary Biliary Cirrhosis Drug Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Primary Biliary Cirrhosis Drug Market Size by Country
  6. 8.2.1 Europe Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Primary Biliary Cirrhosis Drug Market Size by Country (2021-2026)
  8. 8.2.3 Europe Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Country
  2. 9.1.1 Asia-Pacific Primary Biliary Cirrhosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Primary Biliary Cirrhosis Drug Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Primary Biliary Cirrhosis Drug Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Primary Biliary Cirrhosis Drug Market Size by Country
  6. 9.2.1 Asia-Pacific Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Primary Biliary Cirrhosis Drug Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Primary Biliary Cirrhosis Drug Sales by Country
  2. 10.1.1 South America Primary Biliary Cirrhosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Primary Biliary Cirrhosis Drug Sales by Country (2021-2026)
  4. 10.1.3 South America Primary Biliary Cirrhosis Drug Sales Forecast by Country (2027-2032)
  5. 10.2 South America Primary Biliary Cirrhosis Drug Market Size by Country
  6. 10.2.1 South America Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Primary Biliary Cirrhosis Drug Market Size by Country (2021-2026)
  8. 10.2.3 South America Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country
  2. 11.1.1 Middle East and Africa Primary Biliary Cirrhosis Drug Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Primary Biliary Cirrhosis Drug Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Primary Biliary Cirrhosis Drug Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Primary Biliary Cirrhosis Drug Market Size by Country
  6. 11.2.1 Middle East and Africa Primary Biliary Cirrhosis Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Primary Biliary Cirrhosis Drug Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Primary Biliary Cirrhosis Drug Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Primary Biliary Cirrhosis Drug Value Chain Analysis
  2. 12.1.1 Primary Biliary Cirrhosis Drug Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Primary Biliary Cirrhosis Drug Production Mode & Process
  7. 12.2 Primary Biliary Cirrhosis Drug Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Primary Biliary Cirrhosis Drug Distributors
  10. 12.2.3 Primary Biliary Cirrhosis Drug Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst